[
  {
    "ts": null,
    "headline": "ResMed (RMD) Q2 2026 Earnings Call Transcript",
    "summary": "Mick Farrell: Thank you, Sally, and good morning, good afternoon, good evening to all of our shareholders, and welcome to all to ResMed's second quarter fiscal year 2026 earnings call.  For this March and the June quarters, we expect to continue our portfolio management process and maintain mid-single-digit growth across our RCS as we go through that portfolio management.",
    "url": "https://finnhub.io/api/news?id=f0963fd88326ce1a6b4733db5d14db62efd1cc010ba31bf54b6945ef0426afcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769728280,
      "headline": "ResMed (RMD) Q2 2026 Earnings Call Transcript",
      "id": 138301189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Mick Farrell: Thank you, Sally, and good morning, good afternoon, good evening to all of our shareholders, and welcome to all to ResMed's second quarter fiscal year 2026 earnings call.  For this March and the June quarters, we expect to continue our portfolio management process and maintain mid-single-digit growth across our RCS as we go through that portfolio management.",
      "url": "https://finnhub.io/api/news?id=f0963fd88326ce1a6b4733db5d14db62efd1cc010ba31bf54b6945ef0426afcd"
    }
  },
  {
    "ts": null,
    "headline": "ResMed (RMD) Reports Q2 Earnings: What Key Metrics Have to Say",
    "summary": "The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=fc9e70c7b77c8f7a337117e56d4d894bd1d7790d9e61b12ebe2fdb9d44834dd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769725802,
      "headline": "ResMed (RMD) Reports Q2 Earnings: What Key Metrics Have to Say",
      "id": 138302105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=fc9e70c7b77c8f7a337117e56d4d894bd1d7790d9e61b12ebe2fdb9d44834dd6"
    }
  },
  {
    "ts": null,
    "headline": "ResMed (RMD) Q2 Earnings and Revenues Beat Estimates",
    "summary": "ResMed (RMD) delivered earnings and revenue surprises of +4.59% and +2.30%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=8f18b57bad7f07cb20191d76b2838cd115992af8fbb00bc8603512d13a57ad8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769725202,
      "headline": "ResMed (RMD) Q2 Earnings and Revenues Beat Estimates",
      "id": 138302104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "ResMed (RMD) delivered earnings and revenue surprises of +4.59% and +2.30%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=8f18b57bad7f07cb20191d76b2838cd115992af8fbb00bc8603512d13a57ad8d"
    }
  },
  {
    "ts": null,
    "headline": "ResMed (NYSE:RMD) Exceeds Q4 CY2025 Expectations",
    "summary": "Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit of $2.81 per share was 3.2% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=dacbc7c7c479b58987fc94a22948bf38403f34877438883f08e9d4912c8b73ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769724440,
      "headline": "ResMed (NYSE:RMD) Exceeds Q4 CY2025 Expectations",
      "id": 138301190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit of $2.81 per share was 3.2% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=dacbc7c7c479b58987fc94a22948bf38403f34877438883f08e9d4912c8b73ae"
    }
  },
  {
    "ts": null,
    "headline": "ResMed: Fiscal Q2 Earnings Snapshot",
    "summary": "SAN DIEGO (AP) — ResMed Inc. RMD) on Thursday reported fiscal second-quarter net income of $392.6 million. On a per-share basis, the San Diego-based company said it had net income of $2.68.",
    "url": "https://finnhub.io/api/news?id=f81c4cfc1dd75ce1956d6e0ebacb7f6c02c566f1d5a5768d743be8b2bf5dfd97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769721344,
      "headline": "ResMed: Fiscal Q2 Earnings Snapshot",
      "id": 138300214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "SAN DIEGO (AP) — ResMed Inc. RMD) on Thursday reported fiscal second-quarter net income of $392.6 million. On a per-share basis, the San Diego-based company said it had net income of $2.68.",
      "url": "https://finnhub.io/api/news?id=f81c4cfc1dd75ce1956d6e0ebacb7f6c02c566f1d5a5768d743be8b2bf5dfd97"
    }
  },
  {
    "ts": null,
    "headline": "Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026",
    "summary": "Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE)",
    "url": "https://finnhub.io/api/news?id=7e8b9ac677a07229a98ed4ab968078df56878be256cc5c8e515a7f8647ab4947",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769720700,
      "headline": "Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026",
      "id": 138300215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE)",
      "url": "https://finnhub.io/api/news?id=7e8b9ac677a07229a98ed4ab968078df56878be256cc5c8e515a7f8647ab4947"
    }
  },
  {
    "ts": null,
    "headline": "ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript",
    "summary": "ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript",
    "url": "https://finnhub.io/api/news?id=2e39abacb3b28910190d16e1abd485f25584a8a890e3d0979f385a77e06059e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769718181,
      "headline": "ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript",
      "id": 138301793,
      "image": "",
      "related": "RMD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2e39abacb3b28910190d16e1abd485f25584a8a890e3d0979f385a77e06059e3"
    }
  },
  {
    "ts": null,
    "headline": "Are Medical Stocks Lagging  ResMed (RMD) This Year?",
    "summary": "Here is how ResMed (RMD) and Compass Therapeutics, Inc. (CMPX) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=6d88e5263c3a2913936b2118db10ea6637fd50176195220979d6e5853904a1ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769697603,
      "headline": "Are Medical Stocks Lagging  ResMed (RMD) This Year?",
      "id": 138295891,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Here is how ResMed (RMD) and Compass Therapeutics, Inc. (CMPX) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=6d88e5263c3a2913936b2118db10ea6637fd50176195220979d6e5853904a1ad"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Retain Glaukos Stock in Your Portfolio Now",
    "summary": "GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.",
    "url": "https://finnhub.io/api/news?id=46391b08410867e5978a61329aab28e6d63df5ee19643b52f4f699ff9707840e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769693520,
      "headline": "Here's Why You Should Retain Glaukos Stock in Your Portfolio Now",
      "id": 138295712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.",
      "url": "https://finnhub.io/api/news?id=46391b08410867e5978a61329aab28e6d63df5ee19643b52f4f699ff9707840e"
    }
  }
]